Helena Marzo‐Ortega
About
Helena Marzo‐Ortega is a scholar working on Rheumatology, Immunology and Hematology.
According to data from OpenAlex, Helena Marzo‐Ortega has authored 250 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Rheumatology, 107 papers in Immunology and 69 papers in Hematology. Recurrent topics in Helena Marzo‐Ortega's work include Spondyloarthritis Studies and Treatments (192 papers), Rheumatoid Arthritis Research and Therapies (140 papers) and Psoriasis: Treatment and Pathogenesis (105 papers). Helena Marzo‐Ortega is often cited by papers focused on Spondyloarthritis Studies and Treatments (192 papers), Rheumatoid Arthritis Research and Therapies (140 papers) and Psoriasis: Treatment and Pathogenesis (105 papers). Helena Marzo‐Ortega collaborates with scholars based in United Kingdom, United States and Spain. Helena Marzo‐Ortega's co-authors include Paul Emery, Dennis McGonagle, Joachim Sieper, Philip O’Connor, Désirée van der Heijde, E. Hensor, Jürgen Braun, Dennis McGonagle, Xenofon Baraliakos and Martín Rudwaleit and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Frontiers in Immunology.
In The Last Decade
Helena Marzo‐Ortega
228 papers receiving 6.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Helena Marzo‐Ortega United Kingdom | 45 | 5.5k | 3.2k | 2.1k | 995 | 397 | 250 | 6.5k | ||
| J. Brandt Germany | 32 | 6.7k 1.2× | 3.3k 1.0× | 2.4k 1.1× | 807 0.8× | 151 0.4× | 65 | 7.5k | ||
| Denis Poddubnyy Germany | 46 | 7.0k 1.3× | 4.2k 1.3× | 2.2k 1.0× | 1.3k 1.3× | 144 0.4× | 357 | 7.8k | ||
| Dennis McGonagle United Kingdom | 38 | 4.0k 0.7× | 1.6k 0.5× | 1.5k 0.7× | 921 0.9× | 294 0.7× | 123 | 5.5k | ||
| R. B. M. Landewé Netherlands | 22 | 5.0k 0.9× | 2.1k 0.6× | 1.8k 0.8× | 752 0.8× | 111 0.3× | 65 | 5.7k | ||
| Hildrun Haibel Germany | 42 | 6.3k 1.1× | 3.5k 1.1× | 1.9k 0.9× | 1.1k 1.1× | 68 0.2× | 128 | 6.8k | ||
| Muhammad Asim Khan United States | 39 | 3.6k 0.6× | 2.0k 0.6× | 944 0.4× | 330 0.3× | 254 0.6× | 125 | 4.5k | ||
| H Whitelock United Kingdom | 5 | 4.7k 0.9× | 2.2k 0.7× | 1.5k 0.7× | 492 0.5× | 93 0.2× | 5 | 5.0k | ||
| Kurt de Vlam Belgium | 28 | 3.2k 0.6× | 2.0k 0.6× | 1.4k 0.7× | 195 0.2× | 211 0.5× | 172 | 3.8k | ||
| Ulrich Weber Germany | 35 | 3.8k 0.7× | 1.4k 0.5× | 1.1k 0.5× | 1.3k 1.3× | 67 0.2× | 179 | 5.1k | ||
| Sibel Zehra Aydın Canada | 32 | 2.1k 0.4× | 1.2k 0.4× | 982 0.5× | 233 0.2× | 313 0.8× | 145 | 3.1k |
Countries citing papers authored by Helena Marzo‐Ortega
Since
Specialization
Citations
This map shows the geographic impact of Helena Marzo‐Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Marzo‐Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Marzo‐Ortega more than expected).
Fields of papers citing papers by Helena Marzo‐Ortega
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Helena Marzo‐Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Marzo‐Ortega. The network helps show where Helena Marzo‐Ortega may publish in the future.
Co-authorship network of co-authors of Helena Marzo‐Ortega
This figure shows the co-authorship network connecting the top 25 collaborators of Helena Marzo‐Ortega. A scholar is included among the top collaborators of Helena Marzo‐Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Marzo‐Ortega. Helena Marzo‐Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Deodhar, Atul, Victoria Navarro‐Compán, Denis Poddubnyy, et al.. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 11(1). e005081–e005081.
2.
Heijde, Désirée van der, Victoria Navarro‐Compán, R. Landewé, et al.. (2025). 1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis. Annals of the Rheumatic Diseases. 84(3). 382–387.
3.
Marzo‐Ortega, Helena, et al.. (2025). Current understanding of the challenges in the diagnosis and management of spondyloarthritis in older adults. Joint Bone Spine. 93(1). 105981–105981.
4.
Østergaard, Mikkel, R. Lambert, Iris Eshed, et al.. (2024). Hip and pelvis region MRI reference image atlas for scoring inflammation in peripheral joints and entheses according to the OMERACT-MRI WIPE scoring system in patients with spondyloarthritis. Seminars in Arthritis and Rheumatism. 65. 152383–152383.
5.
Michelena, Xabier, Alexandre Sepriano, Sizheng Steven Zhao, et al.. (2024). Exploring the unifying concept of spondyloarthritis: a latent class analysis of the REGISPONSER registry. Lara D. Veeken. 63(11). 3098–3105.
6.
Ramiro, Sofía, Elena Nikiphorou, Walter P. Maksymowych, et al.. (2024). Thresholds for unacceptable work state in radiographic axial spondyloarthritis of four presenteeism and two clinical outcome measurement instruments. Lara D. Veeken. 64(1). 358–366.
7.
Jones, Gareth T., Raj Sengupta, Pedro Machado, et al.. (2023). OA14 Non-steroidal anti-inflammatory drugs reduce sacroiliac joint inflammation in axial spondyloarthritis. Lara D. Veeken. 62(Supplement_2).
8.
Baraliakos, Xenofon, Sofía Ramiro, Martín Rudwaleit, et al.. (2023). POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2. Annals of the Rheumatic Diseases. 82. 875–876.
9.
Harrison, Stephanie R, Xabier Michelena, Dennis McGonagle, et al.. (2023). Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis. Rheumatology Advances in Practice. 8(1). rkae018–rkae018.
10.
Baraliakos, Xenofon, Effie Pournara, Laure Gossec, et al.. (2022). Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial. RMD Open. 8(2). e002303–e002303.
11.
Freeston, Jane, Andrew Barr, Christian P. Selinger, et al.. (2020). Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. Lara D. Veeken. 60(1). 467–470.
12.
Deodhar, Atul, Philip J. Mease, Proton Rahman, et al.. (2020). Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatology and Therapy. 8(1). 135–150.
13.
Marzo‐Ortega, Helena, Ai Lyn Tan, Dennis McGonagle, et al.. (2020). BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. Rheumatology Advances in Practice. 4(2). rkaa043–rkaa043.
14.
Cuthbert, Richard, Abdulla Watad, Evangelos M. Fragkakis, et al.. (2019). Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression. Annals of the Rheumatic Diseases. 78(11). 1559–1565.
15.
Landewé, R., Joachim Sieper, Philip J. Mease, et al.. (2018). Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. The Lancet. 392(10142). 134–144.
16.
McGonagle, Dennis, et al.. (2017). New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Therapeutic Advances in Chronic Disease. 9(3). 77–87.
17.
Abignano, Giuseppina, Philip Laws, F. Galdo, Helena Marzo‐Ortega, & Dennis McGonagle. (2017). FRI0646 Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases. 76. 734–734.
18.
Hébert, Harry L., Jonathan Massey, John Bowes, et al.. (2016). Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. Archives of Dermatological Research. 308(3). 201–205.
19.
Cortés, Adrián, Patrick Danoy, B P Wordsworth, et al.. (2011). Mmp1 Polymorphisms Are Associated with Severity of Radiographic Measures of Ankylosing Spondylitis. Internal Medicine Journal. 41. 22–22.
20.
Braun, Jürgen, Joachim Sieper, Maxime Bréban, et al.. (2002). Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience. Annals of the Rheumatic Diseases. 61. iii51–iii60.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by J. Brandt Breakdown of academic impact, for papers by Denis Poddubnyy Breakdown of academic impact, for papers by Dennis McGonagle Breakdown of academic impact, for papers by R. B. M. Landewé Breakdown of academic impact, for papers by Hildrun Haibel Breakdown of academic impact, for papers by Muhammad Asim Khan Breakdown of academic impact, for papers by H Whitelock Breakdown of academic impact, for papers by Kurt de Vlam Breakdown of academic impact, for papers by Ulrich Weber Breakdown of academic impact, for papers by Sibel Zehra Aydın